Skip to content
Calculadora Capital
ABBVStocksNYSEUSD

AbbVie (ABBV): return calculator

AbbVie (ABBV) shares, a pharmaceutical company specialising in immunology, listed in New York.

US$234.76Latest price · 23 Jun 2026 close

Updated

Type
Stocks
Market
NYSE
Currency
USD
Sector
Healthcare
Data range
2016-07 – 2026-06 · 10 years
Source
Yahoo Finance

US$1,000 invested 9 years ago would be worth today

US$4,707

+370.7% total return

Try your own values in the calculators below.

Return calculator

Pick an amount and a period to see what an investment in AbbVie (ABBV) would be worth today. By default we include reinvested dividends (total return).

Lump sum

What a one-off investment would be worth today.

Value today
US$2,514
Total return
+151.4%
Annualised return
+20.2%

Monthly investing (DCA)

What investing the same amount every month would be worth.

Value today
US$9,750
Profit
US$3,650
Total invested
US$6,100

Estimate before taxes, fees and currency-conversion costs. Past performance does not guarantee future returns.

Investment growth

US$1,000US$5,352
Growth of US$1,000 invested — 2016-07 to 2026-06.

Performance

Annualised return
+18.43%
Best year (2017)
+60%
Worst year (2018)
-1%
Largest drop
-39.1%

Data for the last 10 years · 2016-07 → 2026-06

Comparison with the market

US$1,000 invested vs S&P 500 ETF (SPY):

AbbVie (ABBV)
US$5,352
S&P 500 ETF (SPY)
US$3,849

AbbVie (ABBV) beat S&P 500 ETF (SPY) by US$1,504 (+39%) over this period.

Risk & drawdowns

The largest peak-to-trough drop in the window was -39.1%. An investor who bought near the prior peak would have seen the investment fall significantly before recovering.

Scenarios

Illustrative results based on the available data.

  • US$1,000 5 years ago

    US$2,514

    lump sum, +151.39991373934234% return

  • US$100/mo for 5 years

    US$9,750

    invested US$6,100

  • If it repeats +18.43%/yr for 10 years

    US$5,428

    projection from US$1,000 (hypothetical)

About AbbVie (ABBV)

AbbVie was created in 2013 when Abbott split off its pharmaceutical business. For years it lived off Humira, a drug for immune-system diseases that became the best-selling medicine in the world. With generic versions ("biosimilars") of Humira arriving from 2023, the company now leans on two successors, Skyrizi and Rinvoq, and on Botox and other products gained through the 2020 acquisition of Allergan.

It trades on the New York Stock Exchange (NYSE) under the ticker ABBV and is part of the S&P 500. It is a dividend stock that inherited Abbott's long track record of increases. The big question for investors is whether the growth of Skyrizi and Rinvoq offsets the lost Humira revenue.

Related calculators

Other assets

Frequently asked questions

How much did AbbVie (ABBV) return over the last 10 years?
+435.2% in total, or about +18.43% per year, on a total-return basis (dividends reinvested), between 2016-07 and 2026-06.
Do these calculations include dividends?
By default yes (total return). Turn off "include dividends" to see price-only appreciation.
Do they include taxes or fees?
No. These are estimates before taxes, broker fees and currency-conversion costs.
What currency are the values in?
USD. A euro-based investor also carries EUR/USD currency risk, not reflected here.
Does past performance predict the future?
No. Past performance does not guarantee future returns; this is educational information, not advice.

Sources & methodology

Prices: Yahoo Finance. Monthly series, total return (dividends reinvested). Data through 2026-06-23.

Total return assumes dividends are reinvested; you can turn that off to see price-only appreciation. Values are estimates before taxes, fees and currency-conversion costs.

Page generated and reviewed by the Calculadora Capital editorial team. Last updated 2026-06-23.